Table I.
Time above minimal inhibitory concentration values for vancomycin and meropenem in cortical bone, cancellous bone, and subcutaneous adipose tissue, expressed as minutes and percentages of the dosing interval.
| Parameter | Cortical bone | Cancellous bone | Subcutaneous adipose tissue | Plasma |
|---|---|---|---|---|
| Mean T > MIC, mins (95% CI) | ||||
| Vancomycin, µg/ml | ||||
| 1.0 (low target) | 208 (158 to 259)* | 403 (352 to 453) | 441 (390 to 491) | 449 (399 to 499) |
| 2.0 | 139 (79 to 200)* | 379 (318 to 439) | 433 (373 to 494) | 448 (388 to 508) |
| 4.0 (high target) | 30 (-26 to 86)* | 296 (240 to 352) | 416 (360 to 473) | 446 (390 to 502) |
| Meropenem, µg/ml | ||||
| 0.125 (low target) | 189 (137 to 241)† | 278 (226 to 329) | 331 (280 to 383) | 406 (353 to 458) |
| 0.25 | 177 (130 to 225)† | 256 (208 to 303) | 311 (264 to 359) | 372 (324 to 419) |
| 2.0 (high target) | 45 (17 to 73)† | 144 (116 to 172) | 180 (152 to 208) | 181 (153 to 209) |
| Mean %T > MIC (95% CI) | ||||
| Vancomycin, µg/ml | ||||
| 1.0 | 46 (35 to 58) | 89 (78 to 101) | 98 (87 to 109) | 100 (89 to 111) |
| 2.0 | 31 (18 to 44) | 84 (71 to 98) | 96 (83 to 110) | 100 (86 to 113) |
| 4.0 | 7 (-6 to 19) | 66 (53 to 78) | 93 (80 to 105) | 99 (87 to 112) |
| Meropenem, µg/ml | ||||
| 0.125 | 42 (30 to 54) | 62 (50 to 73) | 74 (62 to 85) | 90 (78 to 102) |
| 0.25 | 39 (29 to 50) | 57 (46 to 67) | 69 (59 to 80) | 83 (72 to 93) |
| 2.0 | 10 (4 to 16) | 32 (26 to 38) | 40 (34 to 46) | 40 (34 to 46) |
p < 0.001 for overall comparison using repeated measurements analysis of variance (F test) for both vancomycin and meropenem T > MIC.
*
p < 0.001 using analysis of variance (paired t-test) for comparison with all other compartments.
†
p ≤ 0.025 using analysis of variance (paired t-test) for comparison with all other compartments.
CI, confidence interval; MIC, minimal inhibitory concentration; %T > MIC, percentage of dosing interval of 450 minutes with concentration above MIC.; T > MIC, time with concentration above MIC